Da	te:2022/6	/15	
	ur Name: Hail		
			ne-related gene signature and infiltrating tumor immune cells
ba	sed on <i>bioinformatics analy</i>	sis in primary esophageal	cancer
Ma	nuscript number (if known)	):	
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time innit for this item.		
			+
		Time frame: pas	ct 26 months
	Grants or contracts from	X None	
•	any entity (if not indicated		
	in item #1 above).		+
	Royalties or licenses	X None	
	,		

Consulting fees

\_X\_\_None

4

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Comment for all and the second	V Nava	
/	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
3	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
	rase summarize the above co	onflict of interest in the fo	ollowing box:

Dat	:e:2022/6	/15				
Υοι	ır Name: Shua	ai Pang				
			ne-related gene signature and infiltrating tumor immune cells			
bas	pased on bioinformatics analysis in primary esophageal cancer					
Ма	Manuscript number (if known):					
rela par to t	ated to the content of your ties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a to so.			
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>			
to t	-	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.			
	tem #1 below, report all su time frame for disclosure i	•	ed in this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as	·			
		needed)				
		Time frame: Since the initia	al planning of the work			
	All support for the present	XNone				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: pas	t 36 months			
	Grants or contracts from	XNone				
	any entity (if not indicated					
	in item #1 above).	V Nene				
'	Royalties or licenses	XNone				

Consulting fees

\_X\_\_None

4

	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
•			
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
12	services	X None	
		l X None	
13	Other financial or non-	XNone	
13	financial interests	X_None	
Ple	financial interests  ease summarize the above co		ollowing box:
Ple	financial interests		ollowing box:
Ple	financial interests  ease summarize the above co		ollowing box:
Ple	financial interests  ease summarize the above co		ollowing box:
Ple	financial interests  ease summarize the above co		ollowing box:

Date:	2022/6/14	
	Yong Li	
Manuscript Title:	The prognostic value of an immune-related gene signature and infiltrating tumor i	immune cells
based on bioinform	atics analysis in primary esophageal cancer	
Manuscript numbe	(if known):	
related to the conto	insparency, we ask you to disclose all relationships/activities/interests listed below to nt of your manuscript. "Related" means any relation with for-profit or not-for-profit ests may be affected by the content of the manuscript. Disclosure represents a comm	third

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
,	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Descipt of annium and	V. Name	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Please summarize the above conflict of interest in the following box:  None.			

		ICIVIJE DISC	LOSURE FURIVI
Date:	2022/6	/14	
	Name:Liang		
			e-related gene signature and infiltrating tumor immune co
based	d on <i>bioinformatics analy</i>	rsis in primary esophageal o	cancer
Manu	script number (if known	):	
relate partie to tra	ed to the content of your es whose interests may b nsparency and does not	manuscript. "Related" me e affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	ollowing questions apply script only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to the	e epidemiology of hypert		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	m #1 below, report all su me frame for disclosure i		d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	planning of the work
	ll support for the present	XNone	
	anuscript (e.g., funding,		
pr	rovision of study materials,		

1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone
		Time frame and 26 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past 36 monthsX_None
3	Royalties or licenses	XNone
4	Consulting fees	XNone

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
•	D .:: .: D .:	V. N	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
	illialiciai liiterests		
Ple	Please summarize the above conflict of interest in the following box:		
	None.		

Date	e:2022/6	/15			
	· Name:Junb				
Man	Nanuscript Title:The prognostic value of an immune-related gene signature and infiltrating tumor immune cel				
base	d on <i>bioinformatics analy</i>	sis in primary esophageal	cancer		
Man	uscript number (if known)	):			
relat parti to tr	ed to the content of your ies whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.		
	following questions apply uscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>		
to th		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.		
	em #1 below, report all su ime frame for disclosure i	• •	ed in this manuscript without time limit. For all other items,		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as	·		
		needed)			
		Time frame: Since the initi	al planning of the work		
. /	All support for the present	XNone			
	manuscript (e.g., funding,				
1 -	provision of study materials,				
	nedical writing, article				
	processing charges, etc.)				
ľ	No time limit for this item.				
		Time frame: pas	st 36 months		
	Grants or contracts from	XNone			
	any entity (if not indicated				
	n item #1 above).				
F	Royalties or licenses	XNone			

Consulting fees

\_X\_\_None

4

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
Г	ease summarize the above co	onflict of interest in the fol	lowing box:

Date:	2022/6/15	
Your Name:	Ling Chen	
Manuscript Title: primary esophagea		lue of an immune-related gene signature and infiltrating tumor immune cells in
Manuscript number	r (if known):	
related to the conte	ent of your manuscrip	ou to disclose all relationships/activities/interests listed below that are ot. "Related" means any relation with for-profit or not-for-profit third by the content of the manuscript. Disclosure represents a commitment
to transparency and	d does not necessaril	y indicate a bias. If you are in doubt about whether to list a rable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone				
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone				
3	Royalties or licenses	X_None				
4	Consulting fees	XNone				

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	-		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V. Name	
11	Stock or stock options	XNone	
12	Descipt of aguinment	X None	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
	rase summarize the above co	onflict of interest in the fo	llowing box: